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ABSTRACT
Hematopoietic stem cells (HSCs) reside in bone marrow (BM) and can be induced 
to mobilize into the circulation for transplantation. Homing and lodgement into BM of 
transplanted HSCs are the first critical steps in their engraftment and involve multiple 
interactions between HSCs and the BM microenvironment.
uPAR is a three domain receptor (DIDIIDIII) which binds urokinase, vitronectin, 
integrins. uPAR can be cleaved and shed from the cell surface generating full-length 
and cleaved soluble forms (suPAR and DIIDIII-suPAR). DIIDIII-suPAR can bind fMLF 
receptors through the SRSRY sequence (residues 88-92).
We previously reported the involvement of soluble uPAR in HSC mobilization. We 
now investigate its possible role in HSC homing and engraftment.
We show similar levels of circulating full-length suPAR in healthy donors 
and in acute myeloid leukemia (AML) patients before and after the pre-transplant 
conditioning regimen. By contrast, levels of circulating DIIDIII-suPAR in AML patients 
are higher as compared to controls and significantly decrease after the conditioning.
We found that suPAR and uPAR84-95, a uPAR-derived peptide which mimics active 
DIIDIII-suPAR, induce a significant increase in Long Term Culture (LTC)-Initiating 
Cells (ICs) and in the release of clonogenic progenitors from LTCs of CD34+ HSCs. 
Further, suPAR increases adhesion and survival of CD34+ KG1 AML cells, whereas 
uPAR84-95 increases their proliferation.
Thus, circulating DIIDIII-suPAR, strongly increased in HSC mobilization, is indeed 
down-regulated by pre-transplant conditioning, probably to favour HSC homing. BM 
full-length suPAR and DIIDIII-suPAR may be involved in HSC lodgement within the 
BM by contributing to a suitable microenvironment.
INTRODUCTION
Hematopoietic stem cells (HSCs) are clonogenic 
cells capable of self-renewal and multilineage 
differentiation. The expression of the CD34 antigen and 
lineage negativity are commonly used in clinics to identify 
human HSCs. The majority of HSCs resides in the bone 
marrow (BM), which provides them with a suitable 
microenvironment, regulating their proliferation/survival 
and differentiation [1-2]. HSCs are retained in the BM 
mainly by their adhesive interactions with the cellular and 
matrix components of the stroma and by interaction with 
specific BM chemokines, in particular the stromal-derived 
factor 1 (SDF1), through the CXCR4 receptor [1-2]. 
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HSCs can be forced to mobilize into the circulation 
[3]. Currently, mobilized peripheral blood (PB) HSCs 
represent the major source of stem cells for autologous 
stem cell transplantion (SCT); they are also increasingly 
used in allogeneic SCT, because of the relative ease of 
collection, the higher yield of stem cells and the shorter 
time to engraftment. The most common mobilizer is the 
granulocyte-colony stimulating factor (G-CSF) [3-4].
Previously, we reported the involvement of the 
urokinase receptor (uPAR) in HSC mobilization [5-
6]. uPAR consists of three homologous domains (DI, 
DII, DIII) anchored to the cell surface by a glycosyl-
phosphatidylinositol (GPI) tail and concentrates the 
proteolytic activity of its ligand, the serine protease 
urokinase (uPA), on the cell membrane, to promote 
plasminogen activation and focused extracellular matrix 
(ECM) degradation [7]. However, uPAR is endowed 
with proteolysis-independent activities; in fact, it binds 
vitronectin (VN), a component abundant in tumor-
associated ECM, interacts with various integrins, 
regulating their activity, mediates uPA-dependent cell 
migration and is required for chemotaxis induced by 
fMet-Leu-Phe (fMLF), a potent leukocyte chemoattractant 
[8]. uPAR can be cleaved, thus generating cell-surface 
truncated forms lacking the N-terminal domain (DIIDIII-
uPAR) [9]. Both full-length and cleaved forms can be 
shed from the cell surface (suPAR and DIIDIII-suPAR, 
respectively). DIIDIII-suPAR exposing residues 88-92 
(SRSRY), is a ligand for the receptors of fMLF (fMLF-Rs) 
and induces migration of various cell types [10-11]. The 
cleaved form of soluble uPAR also regulates the activity 
of inflammatory chemokine receptors, such as MCP-1 and 
RANTES receptors, through fMLF-R activation [12].
We previously found that G-CSF-mobilized 
human HSCs were uPAR-negative; however, G-CSF 
administration to HSC healthy donors up-regulated 
uPAR expression in circulating myeloid precursors and 
monocytic cells, and increased suPAR and DIIDIII-suPAR 
levels in sera. DIIDIII-suPAR likely contributed to HSC 
mobilization by inducing migration of BM-HSCs into the 
circulation [5-6]. In mice, the membrane-anchored uPAR 
marks a subset of BM hematopoietic stem/progenitor 
cells (HSPCs) and promotes the preservation of the 
size of this pool of cells. During G-CSF mobilization in 
mouse, uPAR is released from the HPSC surface, likely by 
plasmin activation; uPAR loss impairs HSPC homing and 
engraftment to the BM microenvironment [13].
We now analyze the levels of circulating soluble 
uPAR forms before and after the myeloablative 
conditioning regimen preceding HSC transplantation, 
to identify variations suggesting a possible involvement 
also in HSC homing and engraftment to BM. Then, we 
explored a potential uPAR role in the cross-talk between 
HSCs and BM. We characterized the presence of the 
different forms of uPAR and of its extracellular ligands, 
uPA and VN, in BM stroma; then, we examined the effects 
of soluble uPAR forms in long term cultures of CD34+ 
HSCs and on the KG1 cell line, as a model for CD34+ 
hematopoietic cells [14].
RESULTS
The level of circulating cleaved forms of soluble 
uPAR are lowered by chemotherapy-based pre-
transplant conditioning
Acute myeloid leukemia (AML) patients, before 
HSC transplantation, are subjected to a myeloablative 
conditioning regimen aimed to eradicate the underlying 
hematologic malignancy and to suppress the host immune 
system. First of all, we evaluated whether the pre-
transplant treatment induced variations in the levels of 
circulating full-length and cleaved suPAR forms.
Circulating uPAR forms were measured in healthy 
donors and in patients using a time-resolved fluorescence 
immunoassay (Figure 1). This technique allows to 
quantitate full-length suPAR and its cleavage products, 
DIIDIII-suPAR and DI-suPAR.
Different levels of the three suPAR forms were 
detected in plasma from four healthy donors. The levels 
of circulating full-length suPAR were similar in healthy 
donors and AML patients, and were not influenced by the 
conditioning regimen. By contrast, the levels of suPAR 
cleavage products (DIIDIII-suPAR and DI-suPAR) were 
significantly higher in AML patients as compared to 
healthy donors; the pre-transplant chemotherapy treatment 
lowered both suPAR forms, although only the DIIDIII-
suPAR decreased in a significant manner.
These results suggest that AML blasts mainly release 
DIIDIII-suPAR; further, the pre-transplant treatment 
decreases circulating DIIDIII-suPAR level, according with 
the previously observed increase of DIIDIII-suPAR during 
HSC mobilization [5].
Bone marrow stroma cells express uPAR and 
its ligands
We then investigated uPAR expression in BM 
stroma. Human CD34+ HSCs residing in the BM do not 
express uPAR [5, 15]. However, uPAR and its extracellular 
ligands may be expressed by BM stroma cells and 
contribute to a suitable microenvironment, thus favouring 
HSC lodgement and engraftment to BM.
The presence of the different uPAR forms and of 
uPAR ligands was evaluated in cultures of human BM 
stroma cells obtained from ten healthy donors (Figure 2A). 
Western blot with a monoclonal antibody able to recognize 
both full-length and cleaved uPAR, showed expression 
of full-length uPAR in some analyzed samples and 
expression of cleaved uPAR in all analyzed samples. 
Interestingly, a polyclonal antibody directed to the 
uPAR
84–95
 region, which contains the binding sequence for 
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fMLF receptors (residues 88–92), recognized the uPAR 
cleaved form in all samples, indicating the exposition of 
this active region. Both uPAR extracellular ligands, uPA 
and VN, were expressed by BM stroma cells.
Membrane-anchored uPAR forms can be easily shed 
from the cell surface by specific phospholipases [7]. In 
fact, both full-length and cleaved suPAR were released in 
cultures of BM cells (Figure 2B).
These results indicate that all the different forms of 
uPAR and both uPAR ligands are expressed in BM stroma.
Soluble uPAR forms increase the 
number of LTC-ICs and the release of 
clonogenic progenitors in long-term cultures of 
PB-CD34+ cells
We then evaluated the potential roles of soluble 
uPAR in the cross-talk between HSCs and the BM 
microenvironment. The effect of full-length suPAR and 
of the DIIDIII-suPAR-derived peptide, uPAR
84-95
, on 
clonogenic progenitors, was studied in long-term cultures 
(LTCs) of PB-CD34+ cells. uPAR
84-95
 covers the uPAR 
region corresponding to residues 84-95, able to bind 
and activate fMLF-Rs, thus mimicking the DIIDIII-
suPAR form which exposes this region [10, 16-17]. 
LTCs, at present, represent the best surrogate in vitro 
of BM hematopoiesis in vivo, because they mimic the 
complex intercellular interactions between the stromal 
microenvironment and stem cells concentrated in niches 
of hematopoietic activity. Highly purified PB-CD34+ cells 
from four donors were grown on irradiated BM-derived 
stroma cells, in the presence or in the absence of suPAR, 
uPAR
84-95
 peptide or its scrambled version. Then, adherent 
cells were harvested and cultured in methylcellulose for 
LTC-ICs calculation. The output of clonogenic progenitors 
in culture medium of LTCs was also assayed; myeloid and 
erythroid colonies were counted as colony forming cells 
(CFCs). Both suPAR and uPAR
84-95
 peptide significantly 
Figure 1: Circulating cleaved forms of suPAR are lowered by chemotherapy-based conditioning regimen. Circulating 
forms of soluble uPAR forms were measured in healthy donors (n=4) and in AML patients (n=5) before and after the pre-transplantation 
chemotherapy-based conditioning regimen, using a time-resolved fluorescence immunoassay [31]. This technique allows to quantitate full-
length suPAR and its cleavage products, DIIDIII-suPAR and DI-suPAR. (*) p≤0.05, as determined by the Student’s t test.
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increased LTC-ICs number as compared to the respective 
controls (Figure 3A). Both stimuli increased also the 
release of clonogenic progenitors (Figure 3B), expanding 
previous results showing this effect only for the uPAR
84-95
 
peptide in LTCs of BM-CD34+ cells [5].
These results indicate that both forms of soluble 
uPAR increase the absolute number of LTC-ICs and, 
possibly as a consequence, the release of clonogenic 
progenitors from BM stroma.
Full-length suPAR increases adhesion of CD34+ 
KG1 cells to fibronectin
suPAR or uPAR
84-95
 peptide may increase the 
number of LTC-ICs in PB-CD34+ LTCs by promoting 
their adhesion to BM stroma. To test this possibility we 
evaluated the effects of both stimuli on the human CD34+ 
KG1 cell line [14].
KG1 cells were incubated with or without full-
length suPAR, uPAR
84-95
 peptide or its scrambled version. 
Then, cells were plated on plastic-bound FN or VN. Cells 
did not adhere to VN (not shown) whereas efficiently 
adhered to FN, which, indeed, is largely present in the BM 
stroma. Only full-length suPAR significantly increased 
KG1 cell adhesion to FN, whereas the uPAR
84-95
 peptide 
did not exert any effect as compared to its scrambled 
control (Figure 4A).
Increased adhesion of suPAR-treated KG1 cells to 
FN may be due to increased levels of specific integrins or 
to the increase of their activation. Therefore, we evaluated 
the levels and the activation state of β1 integrins in 
suPAR-treated or untreated KG1 cells. We focused on β1 
integrins since they generally mediate cell adhesion to FN, 
in particular VLA-4 (α4β1), and VLA-5 (α5β1), which 
are expressed on hematopoietic progenitors and on KG1 
cells [14]. We investigated the activation state of surface 
Figure 2: Bone marrow stroma cells express uPAR and its ligands. Bone marrow stroma cells from ten healthy donors were cultured 
in long-term stem cell medium and then lysed. 50 μg of cell lysate was analyzed by Western blot with a monoclonal antibody able to recognize 
both full-length and cleaved uPAR (first inset), a polyclonal antibody directed to the uPAR
84–95
 region (second inset), and specific antibodies for 
uPA and vitronectin (VN) (Panel A). Bone marrow stroma cells from two further healthy donors were cultured at subconfluence and incubated 
with serum-free culture medium additioned with 1 mg/ml BSA for 3 days at 37°C, 5% CO2. Then, TCA precipitated incubation media and 50 μg 
of cell lysates were analyzed by Western blot with the uPAR specific monoclonal antibody (Panel B).
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β1 integrin by flow cytometry, showing that suPAR 
increased the level of active β1 integrin without affecting 
its expression (Figure 4B). Similar results were obtained 
by immunoprecipitation of active β1 integrin (Figure 4C).
These results suggest that suPAR may act in LTC-
IC assays by promoting CD34+ cell adhesion to the BM 
stroma.
uPAR84-95 increases CD34+ KG1 cell proliferation
An increased proliferation may also contribute to 
the observed increase in the number of LTC-ICs in PB-
CD34+ LTCs; indeed, the increased pro-adhesive effect 
of suPAR, shown in the previous paragraph, may favour 
also cell proliferation. To test this possibility we evaluated 
the effects of both stimuli on KG1 cell proliferation. KG1 
cells were cultured on FN with or without full-length 
suPAR, uPAR
84-95
 peptide or its scrambled version for 0, 
24, 48, 72 hours or 6 days (144h). uPAR
84-95
 significantly 
increased KG1 cell proliferation after 48 h, whereas no 
effect was observed with suPAR treatment (Figure 5).
Thus, only uPAR
84-95
 may directly affect 
proliferation of CD34+ cells, even if it does not exert any 
effect on their adhesion to FN.
Full-length suPAR protects CD34+ KG1 cells 
from apoptosis
suPAR or uPAR
84-95
 peptide may also act in PB-
CD34+ LTCs by protecting HSCs from apoptosis. Thus, 
apoptosis of KG1, induced by serum deprivation, was 
evaluated in the presence or absence of full-length suPAR, 
uPAR
84-95
 peptide or its scrambled version. Apoptosis 
was examined by evaluating cleavage of Caspase3 or 
PARP1. Not starved KG1 cells and KG1 cells treated with 
etoposide were used as negative and positive apoptosis 
control, respectively. First, KG1 cells were serum starved 
for different times to evaluate their survival. Western 
blot analysis showed that Caspase3 and PARP1 cleavage 
already occurred after 24 h, but Caspase3 cleavage was 
more evident after 72 h of serum starvation (Figure 6A). 
Thus, suPAR and uPAR
84-95
 effects on KG1 cell apoptosis 
were examined after 72 h of serum deprivation. Indeed, 
full-length suPAR was able to reduce Caspase3 and 
PARP1 cleavage as compared to the control (Figure 6B), 
suggesting that this uPAR form may protect KG1 cells 
from apoptosis; uPAR
84-95
 did not seem to affect Caspase3 
and PARP1 cleavage as compared to the scrambled 
peptide (not shown).
Figure 3: Soluble uPAR forms increase the number of LTC-ICs and clonogenic progenitors in long-term cultures of 
PB-CD34+ cells. CD34+ cells purified from PB of four donors were plated on BM-derived stroma, allowed to adhere, and cultured for 
5 weeks with or without suPAR, uPAR
84-95
 peptide or its scrambled version. At the end of the fifth week, adherent cells were harvested 
and cultured in methylcellulose for LTC-ICs calculation (Panel A). Output of clonogenic progenitors in culture medium was assayed by 
replating non-adherent cells in methylcellulose for short term cultures; myeloid and erythroid colonies were counted as colony forming 
cells (CFCs) (Panel B). (*) p≤0.05, as determined by the Student’s t test.
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These results suggest that full-length suPAR may 
contribute to the increase of LTC-ICs also by supporting 
their survival.
DISCUSSION
In BM niches, HSCs warrant blood cell homeostasis 
and the maintenance of a stable pool of undifferentiated 
cells. In fact, HSCs possess the capacity for self-renewal 
and multilineage differentiation. Microenvironment 
contributes to maintain a dynamic balance between these 
critical activities [18].
Treatments leading to a better chance of long-term 
remission for malignant blood disorders as leukemia 
can involve myeloablation followed by transplantation 
of matched donor HSCs. Donor HSCs can be forced 
to “mobilize” into the blood to allow their harvesting 
for transplantation. In the recipient, transplanted HSCs 
must first “home” to the BM, then localize and anchor 
within the BM, a process known as lodgement. Homing 
and lodgement of transplanted HSCs are the first critical 
steps in engraftment and involve multiple interactions 
between HSCs and the BM microenvironment. Indeed, 
these interactions dictate the clinical outcome of the 
transplantation [19].
We previously reported the involvement of suPAR 
in HSC mobilization. In fact, we observed that G-CSF 
increased the levels of circulating soluble forms of uPAR, 
both the full-length and the cleaved (DIIDIII) form [5]. 
On the basis of in vitro and in vivo experiments, we 
Figure 4: Full-length suPAR increases adhesion of KG1 cells to fibronectin. Panel A: KG1 cells were resuspended in 1mg/
ml BSA-RPMI at a density of 1x106 cells/ml, pre-incubated with or without suPAR (20 nM), uPAR
84-95
 or scrambled peptide (10 nM) for 
30’ at 37°C and plated on plastic-bound fibronectin for 16 h at 4°C. Attached cells were fixed with 3% PFA and stained with crystal violet; 
stain was eluted and its absorbance at 540 nm was measured by a spectrophotometer. (*) p≤0.05, as determined by the Student’s t test. 
Panel B: suPAR-treated or untreated KG1 cells were fixed with PFA, incubated with antibodies against total or active β1 integrin or with 
nonimmune mouse Ig and, then, with FITC anti-mouse IgG. Cells were finally analyzed by flow cytometry using a FACScan (MFI: Mean 
Fluorescence Intensity). (*) p≤0.05, as determined by the Student’s t test. Panel C: Cell surface antigens of suPAR-treated or untreated KG1 
cells were biotinylated with EZ-link sulfo-NHS-LC-biotin. Cells were lysed; 50 μg of cell lysates were analyzed by Western blot with an 
antibody against total β1 integrin, 400 μg of cell lysates were incubated with an antibody against active β1 integrin or nonimmune mouse 
Ig. Immunocomplexes were then precipitated by protein A-Sepharose, eluted and analyzed by Western blot with horseradish peroxidase-
conjugated streptavidin.
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Figure 5: uPAR84-95 increases KG1 cell proliferation. KG1 cells were serum-starved overnight, plated on plastic-bound fibronectin 
(FN) and cultured with or without full-length suPAR (20nM) (■), uPAR
84-95
 peptide (10 nM) or it scrambled version (10 nM) (▲) for 0, 24, 
48, 72 hours or 6 days (144h). At indicated times, 20μl/well of CellTiter 96 AQueous One Solution Reagent was added. After incubation for 
4 h at 37°C, 5% CO2, the absorbance was determined by an ELISA reader (Bio-Rad) at a wavelength of 490 nm. Fold increase represents 
the ratio between values obtained by treated cells and values obtained by the corresponding control at each time. (*) p≤0.05, as determined 
by the Student’s t test, compared to time 0.
Figure 6: Full-length suPAR protects KG1 cells from apoptosis. KG1 cells were serum starved for indicated times, in the absence 
(Panel A) or in the presence of full-length suPAR or diluent (Panel B). Cells were then lysed and analyzed by Western blot with antibodies 
directed to full-length/cleaved Caspase3 or Parp1; not starved KG1 cells and KG1 cells treated with etoposide were used as negative and 
positive apoptosis control, respectively. The graphs show the O.D. obtained by densitometric scanning of cleaved caspase/Parp1 bands 
normalized to the O.D. of corresponding tubulin/actin bands.
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hypothesized a role for the circulating cleaved suPAR, 
which may contribute to HSC mobilization by directly 
chemoattracting HSCs into the circulation.
On the other hand, in mice, the membrane-anchored 
uPAR, expressed by a subset of BM-HSPCs, contributes 
to the maintenance of this pool of cells in BM [13]. 
In addition, it has been reported that supernatants of 
leukapheresis products (SLPs) of patients mobilized with 
G-CSF, or the various components of SLPs, which include 
the full-length soluble uPAR, increase the chemotactic 
response of HSPCs to SDF-1, even if they are not able to 
directly chemoattract HSCs [20-21]. These observations 
supported the hypothesis that soluble uPAR may be 
involved also in HSC homing/lodgement to BM.
On these basis, we firstly evaluated the levels 
of circulating full-length suPAR, DIIDIII-suPAR or 
the released DI domain in healthy donors and in AML 
patients, before and after the pre-transplant conditioning. 
Unexpectedly, we found similar levels of full-length 
suPAR in donors and in patients before and after the 
conditioning, while both fragments of suPAR were 
significantly higher in patients as compared to healthy 
donors. Circulating suPAR fragments strongly decreased 
in patients after the conditioning, at the point of most 
pronounced aplasia, suggesting that main suPAR forms 
released by AML blasts are probably the cleaved suPAR 
forms.
Indeed, increased suPAR levels have been reported 
in plasma from AML patients without distinction among 
the various forms [22], thus it is possible that the increase 
is due to the specific increase of suPAR fragments. 
Recently, suPAR was measured by ELISA in plasma 
daily taken from a mixed group consisting in ALL, few 
AML and hematologic patients, during the pre-transplant 
conditioning with antithymocyte globulin. suPAR levels 
before the start of the conditioning were only slightly 
elevated as compared to those of healthy controls; during 
the conditioning there was a significant increase in suPAR 
levels only after the first day of treatment, hereafter, 
suPAR levels generally declined [23]. Thus, our results are 
in agreement with previous observations and extend them 
by showing which forms of suPAR are modulated in AML 
and during pre-transplant conditioning. Increased levels of 
cleaved suPAR in AML patients, as compared to control 
healthy donors, may better reflect the number of leukemic 
blasts respect to intact suPAR, as already demonstrated in 
mouse breast cancer [24].
These results are also in agreement with our 
previous observation on the mobilizing effects of cleaved 
DIIDIII-suPAR [5-6], which is indeed reduced by pre-
transplant conditioning and thus cannot counteract homing 
and lodging of HSCs in BM.
uPAR and/or its extracellular ligands may be 
expressed in BM stroma cells, thus also favouring 
engraftment to BM. To elucidate this point, we first 
assessed the presence of the different uPAR forms in 
BM stroma. Since membrane-anchored uPAR forms 
can be easily shed from the cell surface by specific 
phospholipases [7] and act on neighbouring HSCs, we 
explored, by LTCs, the effects of full-length suPAR and 
of a uPAR-derived peptide, uPAR
84-95
, covering the active 
region of DIIDIII-suPAR, on HSCs obtained from PB of 
healthy donors. The addition of both suPAR forms induced 
a significant increase in the absolute number of LTC-ICs 
and in the release of clonogenic progenitors, suggesting 
that they could contribute to the BM engraftment by both 
promoting HSCs proliferation/differentiation and self-
renewal.
Since the increased number of LTC-ICs and 
clonogenic progenitors could be due to various events, 
we investigated the effects of both forms of suPAR on 
adhesion, proliferation or survival of CD34+ KG1 cells, as 
a model of CD34+ hematopoietic cells [14]. Interestingly, 
full-length suPAR induced an increase in adhesion and 
survival of KG1 cells, likely by regulating integrin-
dependent signalling, as previously shown in different cell 
types [25-26]. uPAR
84-95
 did not seem to exert any effect on 
adhesion and survival of KG1 cells, however, it increased 
their proliferation, unlike full-length suPAR. Since cleaved 
uPAR lacking DI does not associate with integrins but 
is a ligand of fMLF-Rs, such as its derived peptide, 
uPAR
84-95
, proliferative effect could be due to the 
stimulation of fMLF-Rs expressed by KG1 cells [5], which 
have been reported to be able to activate proliferative 
signals beside migratory pathways [27-28].
In conclusion, our results show that circulating 
DIIDIII-suPAR, strongly involved in HSC mobilization, 
is indeed down-regulated by pre-transplant conditioning. 
Interestingly, BM full-length suPAR and DIIDIII-suPAR 
could be involved in the maintenance of HSCs within the 
BM by contributing to a suitable microenvironment for 
HSC engraftment since they are present in the BM stroma 
and exert various and significant effects on CD34+ cells.
MATERIALS AND METHODS
Reagents
Anti-uPA polyclonal antibody was from American 
Diagnostica (Greenwich, CT); suPAR from R&D system 
(Minneapolis, MN). The rabbit antibody, recognizing 
the SRSRY sequence of uPAR [29], and uPAR
84-95
 
(AVTYSRSRYLEC) and scrambled (TLVEYYSRASCR) 
peptides were purchased from PRIMM (Milan, Italy). 
Rabbit anti-actin, mouse anti-tubulin antibodies, 
hydrocortisone sodium hemisuccinate, the protease 
inhibitor cocktail were from Sigma-Aldrich (St. Louis, 
MO). Polyclonal anti-caspase3 and anti-VN antibodies, the 
monoclonal anti-PARP1 and anti-β1 integrin antibodies 
were purchased from Santa Cruz (Santa Cruz, CA); 
horseradish peroxidase-conjugated secondary antibodies 
from Bio-Rad (Hercules, CA) and FITC anti-mouse IgG 
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from Jackson Lab. (West Grove, PA). EZ-link sulfo-NHS-
LC-biotin was from Thermo Scientific (Rockford, USA) 
and Streptavidin from GE-Healthcare (UK). ECL detection 
kit was from Amersham International (Amersham, 
England), Polyvinylidene fluoride (PVDF) filters and anti-
active β1 integrin (clone 12G10) antibody from Millipore 
(Windsor, MA). Lymphocyte separation medium was from 
Life Technologies (Gaithersburg, MD); anti-CD3 Abs and 
IgG-conjugated magnetic beads for immunedepletion 
were from Life Technologies (Carlsbad, CA). Fluorescein 
isothiocyanate (FITC)-, peridinin chlorophyll (PerCP)- and 
phycoerythrin (PE)-labeled monoclonal antibodies were 
purchased from Becton Dickinson (Mountain View, CA, 
USA). Long-term stem cell medium and methylcellulose 
were from Stem Cell Technologies (Vancouver, Canada). 
IL-3, G-CSF, GM-CSF, SCF and EPO were from Amgen 
(Thousand Oaks, CA, USA). Fibronectin was from Roche 
(Indianapolis, USA). The kit for Proliferation Assay was 
from Promega (Madison, WI, USA).
Sample collection
Heparinized blood samples were obtained after 
written informed consent (according to the procedures 
outlined by the ethical committee of our institution) from 
5 AML patients [mean age 39±16 years; one of them with 
a favorable cytogenetic risk due to the presence of inv(16), 
two with an intermediate risk showing a normal karyotype 
and the last 2 with an unfavorable risk due to the presence 
of a complex karyotype and t(9;22), respectively] before 
and after the pretransplant conditioning with chemotherapy 
and from four healthy donors. Plasma samples were 
prepared by two successive centrifugations to achieve 
complete platelet removal and were stored at –80°C. 
All patients underwent conditioning with the BU-CY2 
regimen (busulfan, 16 mg/kg; cyclophosphamide, 120 
mg/kg) and received cyclosporin A (CsA) (1 mg/kg·day 
by continuous i.v. infusion from day –1 to day + 20 and 
then 8 mg/kg·day orally) plus short-course methotrexate 
(10 mg/m2 on days +1, +3, and +6) as prophylaxis for 
GVHD. All patients obtained full donor engraftment after 
a mean of 47±15 days from transplant. Heparinized bone 
marrow specimens for BM stroma analysis were obtained 
by aspiration from the posterior iliac crest from 12 healthy 
young donors at the time of allogeneic marrow donation, 
after informed consent.
Cell cultures
For marrow stromal layer, 5x106/ml BM 
mononuclear cells (MNCs) were resuspended in a culture 
medium that consisted of long-term stem cell medium 
(Myelocult; StemCell Technologies) supplemented with 
1x10−6mol/liter hydrocortisone sodium hemisuccinate 
(Sigma), plated into 25-cm2 tissue culture flasks and 
incubated in a humidified atmosphere (37°C, 5% CO2). 
On a weekly basis, the stromal layer cultures were fed by 
complete replacement of the medium and analyzed for 
stromal confluence after 4-5 weeks.
CD34+ KG1 acute myelogenous leukemia cells were 
cultured in RPMI 1640 supplemented with 10% heat-
inactivated fetal bovine serum (FBS).
CD34+ hematopoietic stem cell isolation
Peripheral blood (PB) MNCs were isolated by 
density gradient centrifugation using lymphocyte 
separation medium. After washing with phosphate-
buffered saline (PBS) supplemented with 1% BSA, CD34+ 
cells were highly purified by MiniMacs high-gradient 
magnetic separation columns (Miltenyi Biotec, Auburn, 
CA) according to the manufacturer's instructions. Briefly, 
MNCs were incubated with a hapten-conjugated anti-
CD34+ mAb in the presence of an Fc receptor blocking 
reagent. These cells were subsequently incubated with 
MACS microbeads conjugated to an anti-hapten antibody 
and purified using a high-gradient magnetic separation 
column (Miltenyi Biotec). Positive cells were discharged 
from the column after removal from the magnetic field. 
CD34+ cells were enriched to 95% purity by 2 sequential 
selections through the magnetic cell separator. Purity 
of the positively selected CD34+ cells was evaluated by 
flow cytometry. Purified CD34+ cells were resuspended in 
RPMI medium supplemented with 1% BSA.
LTC-IC assay
For long-term cultures (LTCs), highly purified PB-
CD34+ cells were plated on irradiated (15 Gy of 250kV 
rays) allogeneic bone marrow stromal cells (3x104/cm2) 
at a cell density of 1x105 per well. Culture medium 
consisted of long-term stem cell medium supplemented 
with 1x10-6 M hydrocortisone sodium hemisuccinate. 
LTCs were treated with or without 1μg/ml suPAR, 
uPAR
84-95
 peptide or its scrambled version, incubated at 
37°C for 3 days and then switched at 33°C for 5 weeks. 
Stimuli were weekly re-added to LTC culture medium. 
Weekly removed non-adherent cells were washed and 
used in replating experiment to measure the output of 
clonogenic progenitors. At the end of 5 weeks, also 
stroma-adherent cells were harvested by trypsinization, 
washed three times and assayed for their content of 
clonogenic progenitors, as non-adherent cells. Each 
experimental procedure was performed in duplicate.
Clonogenic progenitors were measured in 
methylcellulose, as previously described [30]. Briefly, 
cells were plated in 1 ml medium per dish (35 mm dishes) 
in the presence of the following growth factor cocktail: 10 
ng/ml IL-3, 50 ng/ml G-CSF, 50 ng/ml GM-CSF, 20 ng/
ml SCF, and 2 U/ml EPO. Myeloid and erythroid colonies 
were counted as colony forming cells (CFCs) after 14 days 
incubation at 5% CO2.
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Adhesion assay
96-well flat-bottom microtiter plates were coated 
with 10 μg/ml vitronectin (VN) or fibronectin (FN) or 
with 1% heat-denatured BSA-PBS as a negative control, 
and incubated overnight at 4°C. The plates were then 
blocked 1 h at room temperature with 1% heat-denatured 
BSA in PBS. KG1 cells were resuspended in 0.1% BSA-
RPMI at a density of 1x106 cells/ml, pre-incubated with or 
without suPAR (20 nM), uPAR
84-95
 or scrambled peptide 
(10 nM) for 30’ at 37°C, plated in previously coated 
plates and incubated for 1 h at 37°C, 5% CO2. Then, 
wells were washed and attached cells were fixed with 3% 
paraformaldehyde in PBS for 10 min and incubated with 
2% methanol for 10 min. The cells were finally stained for 
10 min with 0.5% crystal violet in 20% methanol. Stain 
was eluted by 0.1 M sodium citrate in 50% ethanol, pH 
4.2, and the absorbance at 540 nm was measured by a 
spectrophotometer.
Western blot analysis
Cells were lysed in 1% Triton X-100 in the presence 
of protease inhibitors. The protein content of cell lysates 
was measured by a colorimetric assay (BIORAD); cell 
lysates were electrophoresed in SDS-PAGE (10% for 
uPAR and PARP1 detection, 12% for Caspase3 detection) 
and transferred onto a PVDF filter. The membrane was 
blocked with 5% milk and probed with 1μg/ml of specific 
antibody. Finally, washed filters were incubated with 
horseradish peroxidase-conjugated secondary antibodies 
and bands detected by ECL.
Cell surface biotinylation and 
immunoprecipitation
suPAR-treated or untreated KG1 cells were washed 
in PBS and incubated with EZ-link sulfo-NHS-LC-biotin 
1 mg/ml in PBS for 30’ at room temperature, with constant 
gentle agitation. The supernatant was then removed and 
the reaction stopped by the addition of 100 mM glycine. 
Finally, cells were washed and lysed in RIPA buffer.
Biotinylated samples were incubated 2 h at 4°C with 
30 μg/ml of anti-β1 integrin monoclonal antibodies or 
nonimmune mouse immunoglobulins. Immunocomplexes 
were then precipitated by protein A-Sepharose, eluted and 
analyzed by Western blot with horseradish peroxidase-
conjugated streptavidin diluted 1:3000.
Flow cytometry analysis
suPAR-treated or untreated KG1 cells were washed 
and fixed with 4% PFA for 30’ on ice; fixed cells were 
washed and incubated in blocking solution (5% BSA in 
PBS) for 30’ on ice. Cells were then incubated with 10 
μg/ml anti-β1 integrin antibodies or nonimmune mouse 
immunoglobulins for 3 h on ice, washed and incubated 
with fluorescein isothiocyanate-labeled anti-mouse IgG in 
5% BSA for 1 h on ice. Finally, the cells were washed 
and analyzed by flow cytometry using a FACScan (Becton 
Dickinson, San Josè, CA).
Cell proliferation assay
KG1 cells were incubated in 0.5% FBS-RPMI 
for 16 h at 37°C, 5% CO2. Then, 1x10
5/ml cells were 
plated in FN- or VN-coated 96-well plates (10 μg/ml) 
and incubated with suPAR (20 nM), uPAR
84-95
 (10 nM), 
scrambled peptide (10 nM) or medium. At indicated times, 
20μl/well of CellTiter 96 AQueous One Solution Reagent 
was added. After incubation for 4 h at 37°C, 5% CO2, the 
absorbance was determined by an ELISA reader (Bio-Rad) 
at a wavelength of 490 nm.
Measurement of soluble uPAR forms
The concentration of the three soluble uPAR forms 
was determined using three time-resolved fluorescence 
assays (TR-FIA): TR-FIA1 measuring full-length suPAR, 
TR-FIA2 measuring full length suPAR + DIIDIII-suPAR, 
and TR-FIA4 measuring DI-suPAR [31]. Fluorescence 
was measured using a FluoStar Galaxy fluorometer (BMG 
LabTechnologies) with excitation at 405 nm and emission 
at 615 nm.
Statistical analysis
Differences between groups were evaluated by 
the Student’s t test using PRISM software (GraphPad, 
San Diego, CA). P≤0.05 was considered statistically 
significant.
ACKNOWLEDGMENTS
This work was partly supported by FARB 2014 and 
2015 (ORSA140820 and ORSA158715), Associazione 
Italiana Ricerca sul Cancro (AIRC 2015; IG-16931) 
and MIUR (PON03PE_00060_8 Campania Bioscience). 
We are grateful to Dr. Roberta Cotugno (University of 
Salerno) for assistance with flow cytometry analysis.
CONFLICTS OF INTEREST
The authors declare no conflicts of interest.
REFERENCES
1. Bonig H, Papayannopoulou T. Mobilization of 
hematopoietic stem/progenitor cells: general principles and 
molecular mechanisms. Methods Mol Biol. 2012; 904:1-14.
2. Garrett RW, Emerson SG. Bone and blood vessels: the hard 
and the soft of hematopoietic stem cell niches. Cell Stem 
Cell. 2009; 4:503-6.
Oncotarget60216www.impactjournals.com/oncotarget
3. Pelus LM. Peripheral blood stem cell mobilization: 
new regimens, new cells, where do we stand. Curr Opin 
Hematol. 2008; 15:285-92.
4. Battiwalla M, McCarthy PL. Filgrastim support in 
allogeneic HSCT for myeloid malignancies: a review of 
the role of G-CSF and the implications for current practice. 
Bone Marrow Transplant. 2009; 43:351-6.
5. Selleri C, Montuori N, Ricci P, Visconte V, Carriero MV, 
Sidenius N, Serio B, Blasi F, Rotoli B, Rossi G, Ragno P. 
Involvement of the urokinase-type plasminogen activator 
receptor in hematopoietic stem cell mobilization. Blood. 
2005; 105:2198-205.
6. Selleri C, Montuori N, Ricci P, Visconte V, Baiano A, 
Carriero MV, Rotoli B, Rossi G, Ragno P. In vivo activity 
of the cleaved form of soluble urokinase receptor: a new 
hematopoietic stem/progenitor cell mobilizer. Cancer Res. 
2006; 66:10885-90.
7. Montuori N, Visconte V, Rossi G, Ragno P. Soluble and 
cleaved forms of the urokinase-receptor: degradation 
products or active molecules? Thromb Haemost. 2005; 
93:192-8.
8. Ragno P. The urokinase receptor: a ligand or a receptor? 
Story of a sociable molecule. Cell Mol Life Sci. 2006; 
63:1028-37.
9. Hoyer-Hansen G, Ronne E, Solberg H, Behrendt N, Ploug 
M, Lund LR, Ellis V, Danø K. Urokinase plasminogen 
activator cleaves its cell surface receptor releasing the 
ligand-binding domain. J Biol Chem. 1992; 267:18224-9.
10. Resnati M, Pallavicini I, Wang JM, Oppenheim J, Serhan CN, 
Romano M, Blasi F. The fibrinolytic receptor for urokinase 
activates the G protein-coupled chemotactic receptor FPRL1/
LXA4R. Proc Natl Acad Sci U S A 2002; 99:1359-64.
11. Montuori N, Ragno P. Multiple activities of a multifaceted 
receptor: roles of cleaved and soluble uPAR. Front Biosci. 
2009; 14:2494-503.
12. Furlan F, Orlando S, Laudanna C, Resnati M, Basso V, 
Blasi F, Mondino A. The soluble D2D3(88-274) fragment 
of the urokinase receptor inhibits monocyte chemotaxis 
and integrin-dependent cell adhesion. J Cell Sci. 2004; 
117:2909-16.
13. Tjwa M, Sidenius N, Moura R et al. Membrane-anchored 
uPAR regulates the proliferation, marrow pool size, 
engraftment, and mobilization of mouse hematopoietic 
stem/progenitor cells. J Clin Invest. 2009; 119:1008-18.
14. Smadja-Joffe F, Legras S, Girard N, Li Y, Delpech B, 
Bloget F, Morimoto K, Le Bousse-Kerdiles C, Clay D, 
Jasmin C, Levesque JP. CD44 and hyaluronan binding by 
human myeloid cells. Leuk Lymphoma. 1996; 21:407-20.
15. Béné MC, Castoldi G, Knapp W, Rigolin GM, Escribano 
L, Lemez P, Ludwig WD, Matutes E, Orfao A, Lanza F, 
van't Veer M; EGIL, European Group on Immunological 
Classification of Leukemias. CD87 (urokinase-type 
plasminogen activator receptor), function and pathology in 
hematological disorders. Leukemia. 2004; 18:394-400.
16. Montuori N, Carriero MV, Salzano S, Rossi G, Ragno P. 
The cleavage of the urokinase receptor regulates its multiple 
functions. J Biol Chem. 2002; 277:46932-9.
17. Gorrasi A, Li Santi A, Amodio G, Alfano D, Remondelli P, 
Montuori N, Ragno P. The urokinase receptor takes control 
of cell migration by recruiting integrins and FPR1 on the 
cell surface. PLoS One. 2014; 9:e86352.
18. Heazlewood SY, Oteiza A, Cao H, Nilsson SK. Analyzing 
hematopoietic stem cell homing, lodgment, and engraftment 
to better understand the bone marrow niche. Ann N Y Acad 
Sci. 2014; 1310:119-28.
19. Lam BS, Adams GB. Hematopoietic stem cell lodgment in 
the adult bone marrow stem cell niche. Int J Lab Hematol. 
2010; 32:551-8.
20. Wysoczynski M, Reca R, Ratajczak J, Kucia M, Shirvaikar 
N, Honczarenko M, Mills M, Wanzeck J, Janowska-
Wieczorek A, Ratajczak MZ. Incorporation of CXCR4 into 
membrane lipid rafts primes homing-related responses of 
hematopoietic stem/progenitor cells to an SDF-1 gradient. 
Blood. 2005; 105:40-8.
21. Suárez-Álvarez B1, López-Vázquez A, López-Larrea C. 
Mobilization and homing of hematopoietic stem cells. Adv 
Exp Med Biol. 2012; 741:152-70.
22. Mustjoki S, Alitalo R, Stephens RW, Vaheri A. Blast 
cell-surface and plasma soluble urokinase receptor in 
acute leukemia patients: relationship to classification and 
response to therapy. Thromb Haemost. 1999; 81:705-10.
23. Haastrup E, Andersen J, Ostrowski SR, Høyer-Hansen 
G, Jacobsen N, Heilmann C, Ullum H, Muller K. Soluble 
Urokinase Plasminogen Activator Receptor During 
Allogeneic Stem Cell Transplantation. Scandinavian Journal 
of Immunology. 2011; 73:325-329.
24. Thurison T, Almholt K, Gårdsvoll H, Ploug M, Høyer-
Hansen G, Lund IK. Urokinase receptor cleavage 
correlates with tumor volume in a transgenic mouse 
model of breast cancer. Mol Carcinog. 2015 Mar 25. 
[Epub ahead of print]
25. Wei Y, Lukashev M, Simon DI, Bodary SC, Rosenberg S, 
Doyle MV, Chapman HA. Regulation of integrin function 
by the urokinase receptor. Science. 1996; 273:1551-5.
26. Tang CH, Wei Y. The urokinase receptor and integrins in 
cancer progression. Cell Mol Life Sci. 2008; 65:1916-32.
27. Zhou Y, Bian X, Le Y, Gong W, Hu J, Zhang X, Wang 
L, Iribarren P, Salcedo R, Howard OM, Farrar W, Wang 
JM. Formylpeptide receptor FPR and the rapid growth 
of malignant human gliomas. J Natl Cancer Inst. 2005; 
97:823-35.
28. Rossi FW, Napolitano F, Pesapane A, Mascolo M, Staibano 
S, Matucci-Cerinic M, Guiducci S, Ragno P, di Spigna 
G, Postiglione L, Marone G, Montuori N, de Paulis 
A. Upregulation of the N-formyl Peptide receptors in 
scleroderma fibroblasts fosters the switch to myofibroblasts. 
J Immunol. 2015; 194:5161-73.
Oncotarget60217www.impactjournals.com/oncotarget
29. Montuori N, Bifulco K, Carriero MV, La Penna C, Visconte 
V, Alfano D, Pesapane A, Rossi FW, Salzano S, Rossi G, 
Ragno P. The cross-talk between the urokinase receptor 
and fMLP receptors regulates the activity of the CXCR4 
chemokine receptor. Cell Mol Life Sci. 2011; 68:2453-67.
30. Selleri C, Maciejewski JP, Sato T, Young NS. 
Interferon-gamma constitutively expressed in the 
stromal microenvironment of human marrow cultures 
mediates potent hematopoietic inhibition. Blood. 1996; 
87:4149-4157.
31. Thurison T, Lomholt AF, Rasch MG, Lund IK, Nielsen 
HJ, Christensen IJ, Høyer-Hansen G. A new assay for 
measurement of the liberated domain I of the urokinase 
receptor in plasma improves the prediction of survival in 
colorectal cancer. Clin Chem. 2010; 56:1636-40.
